Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema

Summary

This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision impairment due to center-involved DME

Timeline

Start

2016-04-14

Primary completion

2017-10-23

Completion

2017-10-24

Drugs

Indications